Acute Stroke: Emergency Management and Future Interventions

Mount Sinai Journal of Medicine

Volumn 64, Issue 4-5, 1997, Pages 241-248

  Nassisi, Denise ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Stroke; Subarachnoid hemorrhage; Thrombolytics; Transient ischemic attacks

Indexed keywords

NEUROPROTECTIVE AGENT;

BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBELLUM DISEASE; CEREBROVASCULAR DISEASE; EMERGENCY HEALTH SERVICE; HUMAN; REVIEW;

BRAIN ISCHEMIA; CEREBELLAR DISEASES; CEREBRAL HEMORRHAGE; CEREBROVASCULAR DISORDERS; EMERGENCY MEDICAL SERVICES; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 0031230667     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. American Heart Association. Heart and stroke facts. Dallas, TX: American Heart Association; 1993. p. 10-11.
2. Silver FL, Norris JW, Lewis AJ, Hachinski VC. Early mortality following stroke: A prospective review. Stroke 1984; 15:492-496.
3. Walker MD. Significance of stroke in society. In Stroke: Early pathophysiology and treatment. Summary of the fifth annual Decade of the Brain Symposium, Heros RC, Moderator. Stroke 1994; 25:1877-1881.
4. Camarata PJ, Heros RC, Latchaw RE. "Brain attack." The rationale for treating stroke as a medical emergency. Neurosurgery 1994; 34:144-158.
5. National Stroke Association Consensus Statement. Stroke: The first six hours. Emergency evaluation and treatment. Stroke Clin Updates 1993; 4:1-12.
6. American Heart Association. Guidelines for the management of patients with acute ischemic stroke. Stroke 1994; 25:1901-1914.
7. Brott T, Broderick J, Kothari R. Thrombolytic therapy for stroke. Curr Opin Neurol 1994; 7:25-35.
8. del Zoppo GJ. Thrombolytic therapy in acute ischemic stroke. J Stroke Cerebrovasc Dis 1994; 4:552-558.
9. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemisphere stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274:1017-1025.
10. Multicenter Acute Stroke Trial-Italy (MAST-1) Group. Randomized controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischemic stroke. Lancet 1995; 346:1509-1514.
11. The Multicenter Acute Stroke Trial-Europe Study (MAST-E) Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996; 335: 145-150.
12. Donnan GA, Davis SM, Chambers BR, et al. Trials of streptokinase in severe acute ischemic stroke. Lancet 1995; 345:578-579.
13. The National Institute of Neurologic Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
14. Duke RJ, Block RF, Turpie AGG, et al. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. A randomized controlled trial. Ann Intern Med 1986; 105:825-828.
15. Haley EC, Kassell NF, Torner JC. Failure of heparin to prevent progressing ischemic infarction. Stroke 1988; 19:10-14.
16. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: A randomized trial. Stroke 1993; 14:668-676.
17. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: Brain hemorrhage and management options. Stroke 1984; 15:779-789.
18. Chamorro A, Vila N, Saiz A, et al. Early anticoagulation after large cerebral embolic infarction: A safety study. Neurology 1995; 45:861-865.
19. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79:1-17.
20. Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333:1588-1593.
21. Adams HJ, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 1993; 24:35-41.
22. Barnett HJ, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995; 332:238-248.
23. Meyer FB, Piepgras DC, Sundt TM Jr, Yanaghara T. Emergency embolectomy for acute occlusion of the middle cerebral artery. J Neurosurg 1985; 62:639-647.
24. North American Symptomatic Carotid Endarterectomy Trial Collaborators (NASCET). Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991; 325: 445-453.
25. Meyer FB, Sundt TM Jr, Piepgras DG, et al. Emergency carotid endarterectomy for patients with acute carotid occlusion and profound neurologic deficits. Ann Surg 1986; 203:82-89.
26. Kaneko M, Tanaka K, Shimada T, et al. Long term evaluation of ultra-early operation for hypertensive intracerebral hemorrhage in 100 cases. J Neurosurg 1983; 58: 838-842.
27. Kanno T, Sano H, Shinomiya Y, et al. Role of surgery in hypertensive intracerebral hematoma: A comparison of 305 nonsurgical and 154 surgical cases. J Neurosurg 1984; 61:1091-1099.
28. Kopitnik TA, Kaufman HH. The future prospects of innovative treatment of intracerebral hemorrhage. Neurosurg Clin N Am 1992; 3:703-707.
29. Hunt RC, Hess RN. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg 1968; 8:1920-1968.
30. Haley EC Jr, Kassell NF, Torner JC, et al. The international cooperative study on the timing of aneurysm surgery: The North American experience. Stroke 1992; 23: 205-214.
31. Phillippon J, Grob R, Dagreau F, et al. Prevention of vasospasm in subarachnoid hemorrhage: A controlled study with nimodipine. Acta Neurochir 1986; 82:110-114.
32. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage. British aneurysm nimodipine trial. Br Med J 1989; 298:636-642.
33. Feinberg WM, Albers GW, Barnett HJ, et al. American Heart Association. Guidelines for the management of transient ischemic attacks. Circulation 1994; 89:2950-2965.
34. Henneman PL, Lewis RJ. Is admission medically justified for all patients with acute stroke or transient ischemic attack? Ann Emer Med 1995; 25:458-163.
35. Trembly B. Clinical potential use of neuroprotective agents. A brief overview. Ann NY Acad Sci 1995; 15:1-20.
36. Fisher M, Bogousslavsky J. Evolving toward effective therapy for acute ischemic stroke. JAMA 1993; 270: 360-364.
37. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995; 26:503-513.
38. Schmidley JW. Free radicals in central nervous system ischemia. Stroke 1990; 21:1086-1090.
39. Skaper SD, Leon A. Monosialogangliosides, neuroprotection and neuronal repair processes. J Neurotrauma 1992; 9 (Suppl):S507-516.
40. Argentino C, Sacchetti ML, Toni D, et al. GM1 ganglioside therapy in acute ischemic stroke. Stroke 1989; 20:1143-1149.
41. The Sygen Acute Stroke Study (SASS). Ganglioside GM1 in acute ischemic stroke. Stroke 1994; 25:1141-1148.
42. Fisher M. Potentially effective therapies for acute ischemic stroke. Eur Neurol 1995; 35:3-7.
43. Bowes MP, Rothlein R, Fagan SC, et al. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology 1995; 45:815-819.